Stocks making the biggest moves midday: Oracle, SpaceX, Tempus AI, Rivian & more

Midday moves were mixed: IDEXX rose 20% and Tempus AI gained nearly 12% after earnings beats and higher 2026 revenue forecasts, while Krystal Biotech fell nearly 15% after delaying several treatment data readouts to 2027. Oracle dropped 6% after announcing plans to issue $10 billion in stock and $10 billion in senior notes for its AI build-out; Marvell fell 9% and Lumentum 15% after Marvell agreed to acquire Lumentum in an all-stock deal valued at $115 billion. Rivian gained 10% following a UBS upgrade, while memory and energy stocks declined.

Analysis

The consequential signal is not the earnings beat/miss tally but the cost and credibility of growth. Oracle’s equity-plus-debt funding plan shifts AI expansion risk toward shareholders and creditors: watch offering terms, incremental borrowing costs, and evidence that AI capacity converts to contracted revenue and cash flow. A near-term financing overhang is plausible, but chasing the decline before pricing and capex-return disclosure risks selling after the adjustment. Suppliers and data-center infrastructure names may benefit from spend, though memory weakness argues against assuming broad, immediate AI demand capture.

IDEXX’s raised sales/earnings outlook alongside a lower margin outlook makes execution quality the key issue: volume strength is positive, but costs may absorb part of the growth. Tempus has the cleaner near-term operating signal, but held rather than raised its adjusted EBITDA outlook; revenue growth alone does not establish durable unit economics. For both, valuation and cash conversion—not the headline beat—should determine whether the rally holds.

Krystal’s delayed readouts extend the period investors must fund uncertainty and reduce near-term catalyst density; the earnings beat is secondary. The reported Marvell–Lumentum transaction merits verification: the stated $115 billion value is extraordinary relative to the companies’ scale, and without exchange ratio, financing, and termination terms, the price action is not a reliable read-through. A 2028 close also leaves substantial execution and regulatory risk. SpaceX’s reported wireless discussions remain optionality, not yet evidence of a monetizable distribution or network economics.

Over the next 1–3 months, offering terms, guidance updates, and deal documentation matter more than today’s moves. Over 6–18 months, AI returns and delayed biotech data are the fundamental tests.

Key Decisions for Investors

• ORCL: Avoid adding on the first post-drop session; wait for offering pricing and the next disclosure on AI capex, contracted backlog, and cash-flow conversion. Reassess bearish exposure if financing clears without further deterioration in credit costs or guidance; the thesis weakens if AI revenue conversion accelerates materially.
• TEM / KRYS: Prefer TEM over KRYS as a small, catalyst-aware relative-value position, not an outright growth-duration bet. TEM’s next test is whether data/application growth supports improving cash economics; KRYS needs credible, dated clinical milestones. Reduce the relative position if TEM cuts its EBITDA outlook or KRYS restores timelines with substantiated data.
• MRVL / LITE: Do not trade the reported deal spread until the transaction value, exchange ratio, and closing conditions are confirmed in primary filings. If terms validate, evaluate target-vs-acquirer exposure against the all-stock exchange ratio; the long-dated close creates meaningful deal-break and repricing risk.
• IDXX: Do not chase the sharp rally solely on the beat. Monitor operating-margin guidance and expense growth over the next quarter; sustained volume growth with margin stabilization would validate the move, while further margin cuts would challenge it.